Ian Crocker MD/FACR
Overview
Ian R. Crocker, MD, FACR, retired from practice in October 2016. Dr. Crocker was vice chair of the Department of Radiation Oncology at Emory University School of Medicine in Atlanta, GA. He practiced general radiation oncology and specialized in the treatment of brain and spine tumors and ocular melanoma.
Dr. Crocker was involved in implementing and refining many treatment programs used in the management of brain and eye tumors. He developed innovative therapies for the treatment of ocular melanoma, acoustic neuroma, gliomas and medulloblastoma, to name a few cancers in his specialty area. In collaboration with Emory ophthalmologists, Dr. Crocker developed innovative modern therapies for the treatment of ocular melanomas and metastatic lesions to the eye. He has extensive experience with radiation for the treatment of benign eye conditions.
Dr. Crocker graduated from the University of Saskatchewan, Canada. He completed his residency in internal medicine at University Hospital in London, Ontario, and his residency in radiation oncology in Toronto, Ontario, at The Princess Margaret Hospital. He held the position of assistant professor at Duke University before moving to Emory in 1986.
Dr. Crocker was recognized as a Top Doc by Atlanta Magazine, as well as one of the best doctors in America in his specialty field.
He is a fellow of the prestigious American College of Radiology. Dr. Crocker is also a member of the American Society of Therapeutic Radiology and Oncology, the European Society of Therapeutic Radiology and Oncology, the American Brachytherapy Society, and the International Society of Stereotactic Radiosurgery.
Dr. Crocker initiated three separate radiosurgery programs, each the first of their kind in the state of Georgia. Each of these programs has helped to manage difficult-to-treat brain and eye tumors as well as effectively eliminated the need for certain invasive procedures. Dr. Crocker was the first doctor in the United States to implement image-guided radiation therapy (IGRT) for brain tumors using the Varian On-Board Imaging System. He collaborated on developing a platform to incorporate advanced biologic and functional imaging into the treatment planning and follow-up process. He was also active in the clinical investigation of brain tumors, serving as a co-investigator at Emory of NABTT (New Agents for Brain Tumor Treatment). Prior to this, Dr. Crocker served as co-investigator of brain tumor studies of the Brain Tumor Study Group.
Dr. Crocker authored or co-authored over 60 research articles, and has over 70 published abstracts to his credit. He has been an invited speaker at over 50 national and international meetings.
Academic Appointment
- Professor and Vice Chairman, Department of Radiation Oncology, Emory University School of Medicine
Education
Degrees
- MD from University of Saskatchewan
- Pre-Med from University of Saskatchewan
Research
Focus
- My research is primarily translational and in the past has been focused in three areas: benign diseases, treatment planning and brain and eye tumor treatment. I undertook, with Dr. Ron Waksman, in the early 90s the first animal studies showing that endovascular irradiation was effective in preventing coronary restenosis. I worked to develop and further research a clinical device (Novoste BetaCath System) and was involved in obtaining FDA permission to perform the first human trial of this device at Emory.
Publications
-
Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.
Neurooncol Adv Volume: 4 Page(s): vdac152
01/01/2022 Authors: Scheurer ME; Zhou R; Gilbert MR; Bondy ML; Sulman EP; Yuan Y; Liu Y; Vera E; Wendland MM; Youssef EF -
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).
Neuro Oncol Volume: 23 Page(s): 1125 - 1138
07/01/2021 Authors: Wefel JS; Armstrong TS; Pugh SL; Gilbert MR; Wendland MM; Brachman DG; Roof KS; Brown PD; Crocker IR; Robins HI -
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
J Clin Oncol Volume: 38 Page(s): 3407 - 3417
10/10/2020 Authors: Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ -
Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma.
Sci Rep Volume: 10 Page(s): 7355
04/30/2020 Authors: Buchwald ZS; Tian S; Rossi M; Smith GH; Switchenko J; Hauenstein JE; Moreno CS; Press RH; Prabhu RS; Zhong J -
Dosimetric Factors Related to Radiation Necrosis After 5-Fraction Radiosurgery for Patients With Resected Brain Metastases.
Pract Radiat Oncol Volume: 10 Page(s): 36 - 43
01/01/2020 Authors: Tanenbaum DG; Buchwald ZS; Jhaveri J; Schreibmann E; Switchenko JM; Prabhu RS; Chowdhary M; Abugideiri M; Pfister NT; Eaton B -
Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic Radiosurgery.
Neurosurgery Volume: 85 Page(s): 632 - 641
11/01/2019 Authors: Press RH; Zhang C; Chowdhary M; Prabhu RS; Ferris MJ; Xu KM; Olson JJ; Eaton BR; Shu H-KG; Curran WJ -
Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.
J Neurosurg Volume: 130 Page(s): 797 - 803
03/01/2019 Authors: Jhaveri J; Chowdhary M; Zhang X; Press RH; Switchenko JM; Ferris MJ; Morgan TM; Roper J; Dhabaan A; Elder E -
Fractionated Radiotherapy Is Associated with Lower Rates of Treatment-Related Edema than Stereotactic Radiosurgery in Magnetic Resonance Imaging-Defined Meningiomas.
World Neurosurg Volume: 121 Page(s): e640 - e646
01/01/2019 Authors: Morgan TM; Zaenger D; Switchenko JM; Eaton BR; Crocker IR; Ali AN; Shu H-KG -
Reduced-Volume Tumor Bed Boost is Not Associated with Inferior Local Control and Survival Outcomes in High-Risk Medulloblastoma
Volume: 102 Page(s): E468 - E469
11/01/2018 Authors: Sudmeier LJ; Tian S; Zhang C; Madden NA; Buchwald ZS; Eaton BR; Shu HKG; Crocker IR; Curran WJ; Esiashvili N -
Outcomes of Whole Brain Radiation with Simultaneous In-Field Boost (SIB) for the Treatment of Brain Metastases
Volume: 102 Page(s): E381 - E381
11/01/2018 Authors: Zhong J; Waldman A; Kandula S; Eaton BR; Prabhu RS; Huff SB; Crocker IR; Shu HKG